Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

Study Number

4517425

Phase

II/III

Age Group

Adult

Principal Investigator

Jasmeet Kaur

Purpose

The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.

Check your eligibility for this trial

Check now

Full Title

A Phase 2/3, Multicenter, Randomized Open-label Study of Zanzalintinib vs Everolimus in Participants with Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors

ClinicalTrials.Gov ID

NCT06943755

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.